EMERGENT-5: Cobenfy and Treatment Durability
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 85 Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Psychopharmacology and Psychiatry Updates
Antipsychotics and Weight Gain
EPA vs. DHA: Fish Oil and Treatment-Resistant Depression
AUD Medications and Hepatic Safety
GLP-1 Agonists in Serious Mental Illness: Current Evidence
Get summaries like this every morning.
Free AI-powered recaps of Psychopharmacology and Psychiatry Updates and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.